BACKGROUND The recurrence rates and predictors of recurrence in patients with Solid Pseudopapillary tumors (SPT) are unclear, which makes it challenging to determine the duration of follow-up. The aim of the current study was to perform a systematic review and meta-analysis to determine the recurrence rates and pathologic factors associated with recurrence in patients with SPT. METHODS A PubMed, Scopus, and Web of Science search was conducted to identify studies of SPT published during the last 15 years: (09/2002-09/2017). Studies reporting on patients with SPT and follow-up of >5 years were included. The search strategy was conducted per 2009 PRISMA guidelines. RESULTS A total of 103 studies reporting on 2599 non-metastatic SPT patients were identified. Sixty-nine patients (2.6%) developed recurrence during follow-up. Pooled estimates from studies with a sample size >20 (N = 33) noted an overall recurrence rate of 2% (95% CI 1-2%). Male gender (OR 1.960), positive lymph nodes (OR 11.9), R1 margins (OR 11.1), and LVI (OR 5.5), were associated with a significantly (all p < 0.05) increased risk of recurrence. CONCLUSION Current meta-analysis suggests that only 2% of patients with SPT experience recurrence after resection. These data will guide the treating physicians and patients regarding recurrence rates and help identify patients at increased risk of recurrence during follow-up.

中文翻译：

---

胰腺实性假乳头状瘤患者复发预测指标的系统评价和荟萃分析。

背景实体假乳头状瘤（SPT）患者的复发率和复发预测因素尚不清楚，这使得确定随访时间具有挑战性。本研究的目的是进行系统的回顾和荟萃分析，以确定SPT患者的复发率和与复发相关的病理因素。方法进行PubMed，Scopus和Web of Science搜索以确定过去15年（09 / 2002-09 / 2017）发表的SPT研究。包括有关SPT患者和随访时间超过5年的研究报告。搜索策略是根据2009 PRISMA指南进行的。结果总共鉴定出103项研究，报告了2599例非转移性SPT患者。随访期间有69例患者（2.6％）复发。来自样本量> 20（N = 33）的研究的汇总估计值表明总体复发率为2％（95％CI 1-2％）。男性（OR 1.960），淋巴结阳性（OR 11.9），R1切缘（OR 11.1）和LVI（OR 5.5）与复发风险显着（均p <0.05）相关。结论当前的荟萃分析表明，只有2％的SPT患者在切除后会复发。这些数据将指导主治医师和患者的复发率，并有助于确定随访期间复发风险增加的患者。结论当前的荟萃分析表明，只有2％的SPT患者在切除后会复发。这些数据将指导主治医师和患者的复发率，并有助于确定随访期间复发风险增加的患者。结论当前的荟萃分析表明，只有2％的SPT患者在切除后会复发。这些数据将指导主治医师和患者的复发率，并有助于确定随访期间复发风险增加的患者。